Every 10-Q that Cassava Sciences, Inc. (SAVA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SAVA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SAVA filings page.
Filana Therapeutics, Inc. reported a Q1 2026 net loss of $10.3 million, improving from $23.4 million a year earlier, as research and development spending fell to $4.5 million from $13.7 million after discontinuing its Alzheimer’s program. Cash and cash equivalents were $86.6 million and total stockholders’ equity was $68.1 million as of March 31, 2026. The company carries an accumulated deficit of $506.4 million and has reserved $32.75 million for litigation-related contingencies, including $31.25 million tied to a proposed securities class action settlement. Management believes existing working capital will fund operations for at least the next 12 months while it focuses on developing simufilam for TSC‑related epilepsy under an FDA clinical hold.
Cassava Sciences reported Q3 2025 results. Operating expenses were $11.9M (R&D $3.96M, G&A $7.91M), down sharply from $30.6M a year ago. The quarter’s net loss was $10.8M (basic EPS $0.22 loss). For the nine months, net loss totaled $78.4M versus net income of $3.3M in 2024, which benefited from a large non‑cash warrant liability gain.
Cash and cash equivalents were $106.1M at September 30, 2025; net cash used in operations for the nine months was $22.5M. Total liabilities were $48.2M, primarily payables and accruals, and stockholders’ equity was $81.6M. The company recorded litigation reserves of $35.25M, including $31.25M related to potential settlement of a consolidated securities action. It previously paid a $40M SEC civil penalty in November 2024. Management believes working capital is sufficient for at least the next 12 months. Shares outstanding were 48,307,896 as of November 10, 2025.
Cassava Sciences reported a net loss of $44.2 million for the quarter and $67.6 million for the six months ended June 30, 2025, driven by $40.3 million of general and administrative expense and $5.1 million of research and development expense in the quarter. Cash and cash equivalents totaled $112.4 million, down from $128.6 million at year-end 2024, while total assets fell to $135.4 million and stockholders' equity declined to $88.0 million. Accounts payable and accrued expenses increased materially to $42.8 million, contributing to total liabilities of $47.4 million.
The company recorded $35.25 million of litigation loss contingencies as of June 30, 2025, including a $31.25 million reserve related to the consolidated securities action and a $4.0 million reserve related to an anti-SLAPP matter. Cassava paid a $40 million civil penalty to settle an SEC enforcement matter in 2024 and continues to cooperate with DOJ inquiries. Management states working capital is sufficient for at least the next 12 months. Operationally, the company completed the phase-out of its Alzheimer’s program in Q2 2025, entered a Yale license for simufilam in TSC-related epilepsy with up to $4.5 million in milestones plus tiered royalties, and announced positive preclinical TSC results showing a dose-related reduction in seizures in a mouse model.